• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

The pathogenesis of ovarian myxoma: a neoplasm sometimes arising from other ovarian stromal tumors.

作者信息

Roth Lawrence M, Gaba Arthur R, Cheng Liang

机构信息

Department of Pathology, Indiana University School of Medicine, Indianapolis, Indiana 46202-5120, USA.

出版信息

Int J Gynecol Pathol. 2013 Jul;32(4):368-78. doi: 10.1097/PGP.0b013e3182630d4e.

DOI:10.1097/PGP.0b013e3182630d4e
PMID:23722509
Abstract

Ovarian myxoma is a rare distinctive benign ovarian stromal neoplasm that occurs predominantly in young women and is hormonally inactive. Although typically classified as an ovarian stromal tumor, its exact pathogenesis remains uncertain. We report 4 cases of ovarian myxoma, 3 of which were associated with another type or other types of ovarian stromal tumor and 1 occurred as a pure myxoma. In 2 cases, the myxoma arose from a sclerosing stromal tumor, and the third, most likely arose from a luteinized theca cell tumor (LTCT). Myxoid transformation of the connective tissue of the parent neoplasm appears to be a precursor of ovarian myxoma in some instances. We believe that the occurrence of trisomy 12 or other genetic abnormalities may play a role in this transformation. Whether or not associated with another type of ovarian stromal tumor, ovarian myxoma can be suspected macroscopically by its cystic gelatinous appearance and sharp circumscription. The most important differential diagnosis is a low-grade sarcoma with myxomatous features. We believe that myxomas arising from different anatomic sites likely are genetically, histologically, and biologically distinct. For purposes of classification, they should be considered as separate tumor types.

摘要

相似文献

1
The pathogenesis of ovarian myxoma: a neoplasm sometimes arising from other ovarian stromal tumors.
Int J Gynecol Pathol. 2013 Jul;32(4):368-78. doi: 10.1097/PGP.0b013e3182630d4e.
2
Histologic and immunohistochemical evidence for considering ovarian myxoma as a variant of the thecoma-fibroma group of ovarian stromal tumors.将卵巢黏液瘤视为卵巢间质瘤中纤维瘤-卵泡膜瘤组变体的组织学和免疫组化证据。
Arch Pathol Lab Med. 1993 Aug;117(8):802-8.
3
On the pathogenesis of sclerosing stromal tumor of the ovary: a neoplasm in transition.关于卵巢硬化性间质瘤的发病机制:一种处于转变中的肿瘤。
Int J Gynecol Pathol. 2014 Sep;33(5):449-62. doi: 10.1097/PGP.0000000000000084.
4
Microcystic stromal tumor of the ovary: report of 16 cases of a hitherto uncharacterized distinctive ovarian neoplasm.卵巢微囊性间质瘤:16例一种迄今未明确特征的独特卵巢肿瘤的报告
Am J Surg Pathol. 2009 Mar;33(3):367-75. doi: 10.1097/PAS.0b013e31818479c3.
5
[Stromal luteoma of the ovary. Differential diagnosis of steroid cell tumors].[卵巢间质黄体瘤。类固醇细胞瘤的鉴别诊断]
Ann Pathol. 1992;12(3):193-7.
6
Involuting luteinized thecoma of the ovary.卵巢黄体化滤泡膜细胞瘤。
Int J Gynecol Pathol. 2014 Jan;33(1):23-9. doi: 10.1097/PGP.0b013e31827db06f.
7
Luteinized thecomas (thecomatosis) of the type typically associated with sclerosing peritonitis: a clinical, histopathologic, and immunohistochemical analysis of 27 cases.与硬化性腹膜炎相关的典型类型的黄素化卵泡膜瘤(卵泡膜瘤病):27例临床、组织病理学及免疫组化分析
Am J Surg Pathol. 2008 Sep;32(9):1273-90. doi: 10.1097/PAS.0b013e3181666a5f.
8
Signet ring stromal cell tumor revisited and related signet ring cell lesions of the ovary.再次探讨印戒状间质细胞瘤和卵巢的相关印戒状细胞病变。
Hum Pathol. 2014 Mar;45(3):636-42. doi: 10.1016/j.humpath.2013.09.012. Epub 2013 Oct 3.
9
Thecoma of the ovary: a report of 70 cases emphasizing aspects of its histopathology different from those often portrayed and its differential diagnosis.卵巢卵泡膜细胞瘤:70 例报告,强调了其组织病理学与通常描述的不同的方面及其鉴别诊断。
Am J Surg Pathol. 2014 Aug;38(8):1023-32. doi: 10.1097/PAS.0000000000000252.
10
Ovarian fibrothecoma with massive edema.
J Med Invest. 2000 Aug;47(3-4):148-51.